Hosted on MSN1h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
FiercePharma9h
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
GlobalData on MSN11h
MindMed doses first subject in Phase III Panorama study of GAD tablet
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...
Optimistic Buy Rating for Mind Medicine’s MM120 Amid Promising Phase 3 Progress and Strong Phase 2b Results
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...
Le Lézard10h
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...
H.C. Wainwright lifts Axsome stock target to $190 on FDA nod
Selvaraju highlighted Axsome earlier in the week as a Top Pick within their coverage universe, reiterating the Buy rating and emphasizing the company's strengthened position following the FDA's green ...
BuzzFeed on MSN21h
After The Fall Of Roe V Wade, We Asked Men If They'd Be Willing To Take Male Birth Control And Here's What They Said
Following the Supreme Court’s overturning Roe v. Wade, conversations about male hormonal birth control have never been more ...